SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla inks MoU with Russian firm for HIV, Hepatitis C drugs

20 Jun 2016 Evaluate

Cipla, a global pharmaceutical company has signed a Memorandum of Understanding (MoU) with Russia’s National Immunobiological Company to innovative antiviral medical products for HIV and Hepatitis C treatment and to technology transfer and active pharmaceutical ingredients (API) manufacturing. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019 total market share for anti-HIV drugs will increase to 60%.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

Cipla Share Price

1232.95 -5.35 (-0.43%)
20-Apr-2026 14:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.90
Dr. Reddys Lab 1235.10
Cipla 1232.95
Zydus Lifesciences 936.50
Lupin 2327.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×